肿瘤细胞治疗研究
MODALITY HUB
FOR TREATMENT
现在就能报名的（招募中）排在最前，共 0 项。同一状态内中国中心优先。信息来自 ClinicalTrials.gov 与 CDE 公开登记。能否入组、费用与可及性，以登记原文和主治医生判断为准。
FOR RESEARCH
EGFR TKIs suppress MUC1 glycosylation through the PI3K/AKT/SP1/C1GALT1 pathway to enhance TnMUC1 CAR-T efficacy in EGFR-mutant NSCLC.
Advances and challenges in CAR-T cell therapy for head and neck squamous cell carcinoma.
Emerging Landscape of CAR-T Cell Therapy in Colon Cancer: Mechanistic Insights, Clinical Advances, Challenges, and Future Directions.
Advances and challenges in CAR-T cell therapy for breast cancer: from molecular design to clinical application.
CAR-T cell therapy in breast cancer management: expanding horizon and overcoming challenges beyond hematologic cancers.
CAR-T therapy in non-small cell lung cancer: Clinical prospects, potential, and strategies for cardiotoxicity management.
CAR T cells in lung cancer: Targeting tumor-associated antigens to revolutionize immunotherapy.
Advancing Cholangiocarcinoma Care: Insights and Innovations in T Cell Therapy.
Advances in CAR T Cell Therapy for Non-Small Cell Lung Cancer.
Chimeric antigen receptor T-cell therapy: challenges and opportunities in lung cancer.
MEMBER ACCOUNT
登录成功会直接打开下一页。
